Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
Adaptive currently offers a clinical immunosequencing assay for monitoring minimal residual disease in multiple myeloma and acute lymphoblastic leukemia.
The firm, Phenomix Sciences, anticipates that its test will help drive adoption of medications for obesity at a time when patients are reluctant to take them.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.
The high-throughput, scalable BD Cor system for infectious disease diagnostics is now available in Europe with the firm's BD Onclarity HPV assay.
CPIC wants to issue guidelines for non-actionable genes, standardize PGx terms, and work with groups like ClinGen and ClinVar to expand use of its guidelines.
The researchers found differences in mutational patterns among their African-American patients and that liquid biopsies seem to catch metastases early.
The firm is validating two biomarkers that it hopes will stratify patients for its investigational drug for pediatric minimally verbal autism.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.